Latest Biotechnology News

Page 17 of 57
Imagion Biosystems has completed manufacturing its MagSense® HER2 imaging agent, progressing toward a Phase 2 clinical trial with strong collaborations and a recent AU$3.5 million capital raise.
Ada Torres
Ada Torres
7 Oct 2025
Mesoblast Limited reports a robust 66% increase in Ryoncil revenues for Q2 2025, driven by strong market adoption and new Medicare reimbursement codes.
Ada Torres
Ada Torres
7 Oct 2025
The U.S. FDA has lifted the clinical hold on Neurizon Therapeutics’ lead drug candidate NUZ-001, enabling its entry into a major ALS platform trial set for Q4 2025. This regulatory milestone accelerates the company’s clinical development and opens doors for broader neurodegenerative applications.
Ada Torres
Ada Torres
6 Oct 2025
Arovella Therapeutics has demonstrated that its novel CLDN18.2 CAR-T cells effectively eliminate pancreatic cancer cells in vitro, matching the performance of a leading competitor’s product. The company is now advancing this CAR into its innovative iNKT cell platform to tackle solid tumours.
Ada Torres
Ada Torres
2 Oct 2025
Chimeric Therapeutics reports encouraging Phase 1B data from its ADVENT-AML trial, showing safety and multiple complete responses in high-risk AML patients treated with CORE-NK combined with standard therapies.
Ada Torres
Ada Torres
2 Oct 2025
(E,E)-bisantrene, Race Oncology’s lead anticancer candidate, operates by binding to G4-DNA and RNA structures, revealing a novel mechanism that disrupts key cancer drivers including the MYC gene.
Ada Torres
Ada Torres
2 Oct 2025
Anatara Lifesciences has raised $1.2 million through a discounted share placement to fund its Anti-Obesity project and explore new opportunities. The capital injection reflects strong institutional support amid ongoing pipeline development.
Ada Torres
Ada Torres
1 Oct 2025
Radiopharm Theranostics has received a positive safety recommendation to increase the dose of its radiotherapeutic 177Lu-RAD202 in the Phase 1 HEAT trial for HER2-positive advanced solid tumors, signaling promising early results.
Ada Torres
Ada Torres
1 Oct 2025
Biome Australia Limited has reported a record-breaking $5.94 million in sales revenue for Q1 FY26, surpassing forecasts and accelerating toward its ambitious Vision 27 revenue goals.
Ada Torres
Ada Torres
1 Oct 2025
Paradigm Biopharmaceuticals has dosed participants in its pivotal Phase 3 trial for knee osteoarthritis across the US and Australia, progressing steadily towards a mid-2026 interim analysis.
Ada Torres
Ada Torres
30 Sept 2025
Invex Therapeutics Ltd has had its trading suspension lifted following the announcement of a material acquisition, signaling a pivotal moment for the biotech company.
Ada Torres
Ada Torres
30 Sept 2025
Invex Therapeutics reveals the collapse of confidential acquisition negotiations following shareholder unrest and potential board changes, clarifying recent unusual trading activity.
Ada Torres
Ada Torres
30 Sept 2025